Integrichain Blog

Blog

Maze representing the challenges faced with pharmaceutical market access

Market Access Blogs Michael Kerman
April 19, 2022

The Top 10 Market Access Challenges

5 Minute Read

We explore the 10 most common challenges facing Market Access operations, based on over 15 years of experience with more than 250 pharma manufacturers.

Three Pharma regulatory consultants working at a table and planning their pharma gross-to-net strategy

Contracts & Pricing Jeff Baab Jason Zemcik
April 11, 2022

Best Price and Copay Challenges: Frequently Asked Questions

11 Minute Read

Common manufacturer concerns on best price calculations, copay accumulators and maximizers, and 340B management as the effective date for the CMS Final Rule approaches.

Contracts & Pricing Brian Bumpus Matt Cunningham
March 28, 2022

Medicare Part B Sequestration Update

3 Minute Read

Regulatory Market Update Updates for Pharma Manufacturers As always, if you have questions on any of the content found in this or previous market updates, please reach out to...

Launch Readiness Dave Weiss
March 24, 2022

Best Practices: Achieving Your Pre-Launch Sales Forecasts

6 Minute Read

Market access leaders from DBV Technologies, Karyopharm Therapeutics, and Sesen Bio discuss critical factors in a successful launch and ways to achieve pre-launch forecasts.

ICyte Platform Josh Halpern
March 7, 2022

Unifying IntegriChain’s Services & Support: Customer Support and Value Realization

4 Minute Read

In his second unification-focused blog, President and COO Josh Halpern discusses IntegriChain's investment in customer support to better augment the value for customers and end-users.

Overcoming Challenges in Rare Disease

Market Access Blogs Dave Weiss
February 28, 2022

Overcoming Drug Commercialization Challenges in Rare Disease

5 Minute Read

Solutions to common challenges that manufacturers face when commercializing rare and orphan disease therapies.

Contracts & Pricing Olivia Nweze Gourab Khan Ben Fanelli
February 24, 2022

Branded Pharma Fee: Manufacturer Considerations

5 Minute Read

And other regulatory updates on Line Extension guidance, the upcoming DUNS number transition, and emergency 340B flexibilities.

ICyte Platform Josh Halpern
February 15, 2022

Unifying IntegriChain’s Services & Support: Data Management

4 Minute Read

President and COO Josh Halpern discusses the current and future capabilities of the integrated applications, analytics, and datastores within the ICyte Platform.

Gross-to-Net Jen Sharpe
February 3, 2022

Forecasting for the Future

2 Minute Read

How manufacturers can leverage successful returns and inventory pipeline reserve methodologies for long-term benefits.

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article